The Avience Biomedicals Ltd IPO opens for subscription on June 18, 2026 and closes on June 22, 2026. It is an NSE SME book-built IPO from a healthcare diagnostics and medical devices company.
For SME IPOs, investors also need to consider valuation, liquidity, business sustainability, client concentration, and the higher minimum application amount.
This guide explains the Avience Biomedicals IPO in a simple, investor-friendly way. You will find the IPO dates, price band, lot size, GMP, company profile, financials, strengths, and risks.
Avience Biomedicals Ltd IPO: Key Details at a Glance
Here is everything that matters, in one table.
| IPO Open Date | June 18, 2026 |
| IPO Close Date | June 22, 2026 (cut-off 5 PM) |
| Issue Type | Book-built SME issue (100% fresh issue) |
| Price Band | ₹196 to ₹208 per share |
| Face Value | ₹10 per share |
| Lot Size | 1,200 shares |
| Minimum Investment (1 lot) | ≈ ₹2,49,600 at the upper band |
| Total Issue Size | ≈ ₹30.24 crore (14,53,800 fresh shares) |
| Listing Platform | NSE SME (Emerge) |
| Registrar | Skyline Financial Services Pvt Ltd |
| Lead Manager | Fintellectual Corporate Advisors Pvt Ltd |
| Market Maker | Asnani Stock Broker Pvt Ltd |
| Basis of allotment | June 23, 2026 |
| Refunds initiated | June 24, 2026 |
| Shares credited to demat | June 24, 2026 |
| Listing on NSE SME | June 25, 2026 (tentative) |
About Avience Biomedicals
Avience Biomedicals is an ISO-certified diagnostics and medical-device company that runs its manufacturing operations out of Noida, Uttar Pradesh. In plain terms, it makes the kits and machines that pathology labs and hospitals use to detect disease.
The product range is wide. It covers rapid test kits, molecular diagnostics, biochemistry analysers and reagents, haematology analysers, serology products and other medical devices, sold largely under its Avienbio brand. Its test kits target common infections like dengue, malaria, HIV, hepatitis and typhoid.
Customers sit on both sides of the market. Avience Biomedicals supplies pathology labs, microbiology labs, hospitals and research centres across India and a few overseas markets, working through B2B and B2G (business-to-government) channels. It also acts as a distributor and trader of medical equipment. As of January 31, 2026, it employed 75 permanent staff and 33 contractual workers.
Avience Biomedicals IPO GMP Today:
As of June 17, 2026, IPO Watch reported the Avience Biomedicals IPO GMP at around ₹63, compared with ₹70 on June 16 and ₹40 on June 15. At the upper issue price of ₹208, this implies an indicative grey market premium of around 30%.
However, GMP should be treated carefully.
Grey Market Premium is an unofficial market indicator. It is not regulated by SEBI, NSE or BSE. GMP can change quickly before listing, and a high GMP does not guarantee listing gains. For SME IPOs, GMP-driven decisions can be risky because liquidity after listing may be limited.
A practical investor should use GMP only as a sentiment indicator. The real decision should depend on the company’s business model, valuation, financial performance, use of funds, risk factors and personal risk appetite.
For a beginner-friendly explanation, read Acumen’s guide: What is GMP in IPO?
Avience Biomedicals’ Financial Performance
On a consolidated basis, the growth story looks impressive. Revenue nearly doubled in FY25, and profit more than tripled.
| Period (Consolidated) | Revenue (₹ Cr) | Net Profit (₹ Cr) |
| FY24 | 24.37 | 2.14 |
| FY25 | 45.97 | 7.23 |
| 10M FY26 (to 31 Jan 2026) | 41.94 | 5.74 |
The return ratios are eye-catching too: an average return on net worth of about 44.7% and an average EPS near ₹14.9. At the ₹208 upper band, the issue is priced at roughly 15.8 times FY25 earnings, with a post-issue price-to-book of about 1.9 times.
Strengths of Avience Biomedicals IPO
1. Healthcare and diagnostics exposure
Avience Biomedicals operates in the healthcare diagnostics and medical devices segment. Diagnostics is an important part of India’s healthcare ecosystem because hospitals, pathology labs and research centres need reliable testing products.
2. Diversified product portfolio
The company is not dependent on only one product. Avience Biomedicals sells diagnostic kits, IVD products, analysers, reagents, serology products and related medical devices. This diversification can reduce product concentration risk, although category-wise revenue contribution should be checked in the RHP.
3. Strong recent revenue and profit growth
The company’s FY25 revenue and profit growth are attractive. Revenue almost doubled from FY24 to FY25, while profit increased more sharply.
4. Fresh issue structure
The issue is a fresh issue, so the money raised goes to the company. This can support business expansion if the funds are used efficiently.
5. Planned manufacturing expansion
A major part of the IPO proceeds is proposed for setting up a new manufacturing unit at YEIDA Medical Device Park in Uttar Pradesh.
Key Risks Investors Should Know
1. SME IPO risk
A SME IPO may be more volatile than a mainboard IPO. Post-listing liquidity may be limited, spreads can be wider, and price movements may be sharper.
2. High minimum application amount
The minimum investment is around ₹2.49 lakh at the upper price band. This is a large ticket size for many retail investors.
3. GMP can reverse quickly
The IPO GMP has already moved from ₹40 to ₹70, then to around ₹63 in a short period. This shows that grey market sentiment can change quickly.
4. Sustainability of growth
The company has delivered strong recent numbers, but investors should check whether the profit jump is sustainable. One strong year is encouraging, but long-term valuation depends on repeatable earnings.
5. Execution risk
The company plans to spend a large part of IPO proceeds on a new manufacturing unit. New capacity can support growth, but delays, cost overruns or lower-than-expected demand can affect returns.
6. Regulatory and quality risk
Diagnostics and medical devices are sensitive healthcare categories. Product quality, certifications, compliance and regulatory standards matter. Any quality issue may affect reputation, approvals and customer trust.
How to Apply for the Avience Biomedicals IPO
Investors can apply through ASBA net banking or through UPI using a broker platform. IPO Watch states that investors can apply via ASBA through bank accounts or through stock brokers using UPI.
Basic steps:
- Log in to your demat and trading account.
- Go to the IPO section.
- Select Avience Biomedicals Ltd IPO.
- Enter the bid quantity and price.
- For better allotment chances, many investors bid at the cut-off or upper price band.
- Approve the UPI mandate before the deadline.
- Check allotment status after finalisation.
New investors can visit Acumen Capital Market to explore demat and investment services. You may also read: IPO Allotment Process
Conclusion
The Avience Biomedicals Ltd IPO brings a growing diagnostics and medical devices company to the NSE SME platform. The company has reported strong revenue and profit growth, and the IPO proceeds are planned for manufacturing expansion, working capital and corporate purposes.
The IPO also has clear risks. The minimum application amount is high, the issue is on the SME platform, GMP is unofficial, and the sustainability of recent growth needs careful review. Investors should not treat grey market premium as a guaranteed listing signal.
For informed investors with SME IPO experience and a higher risk appetite, Avience Biomedicals may be worth studying in detail. For cautious or first-time investors, the safer route is to read the offer document, understand the risks and avoid applying only for listing gains.
Frequently Asked Questions
Q1. Is the Avience Biomedicals IPO worth applying for?
The company shows strong recent growth and high return ratios, but the issue looks fully priced, and the profit surge may not be repeatable. Read the RHP, weigh the steep minimum ticket, and match the decision to your own risk appetite.
Q2. How much money do I need to apply for the Avience Biomedicals IPO?
You need about ₹2,49,600 for one lot of 1,200 shares at the upper price band of ₹208. The amount stays blocked through UPI until allotment.
Q3. What will Avience Biomedicals do with the IPO money?
The IPO is a 100% fresh issue. Avience Biomedicals plans to use the funds for manufacturing expansion, working capital needs and general corporate purposes.
Q4. Should I apply for listing gains or long-term holding?
Apply only after checking the company’s fundamentals and risks. GMP may suggest listing interest, but it is unofficial and can change before listing.
Q5. What are the biggest risks in this IPO?
Key risks include rich valuation, uncertain profit sustainability, customer and supplier concentration, China import exposure and SME IPO liquidity risk.
Q6. Is the Avience Biomedicals IPO fairly priced?
At the upper price band, the IPO appears fully priced. The company has strong recent growth, but investors should check whether that growth can continue.
Q7.What are my chances of allotment?
Allotment depends on subscription demand. If the IPO is oversubscribed, shares are allotted through a lottery, and refunds are expected from June 24, 2026.